GLP1_NEW
Medi41 sc
MEDI41_SC
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.43 (0.01 to 31.66) | 0.65 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.48 (0.01 to 32.78) | 0.65 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.03 (0.13 to 12.37) | 0.56 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.81 (0.08 to 12.14) | 0.65 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.12 (0.33 to 4.81) | 0.57 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.13 (0.01 to 0.85) | 0.92 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.48 (0.01 to 35.75) | 0.58 |